• The line-up includes two new para-athletes – Indonesian para cyclist Muhammad Fadli Imamuddin and Malaysian para-athletics sprinter Muhammad Ammar Aiman Nor Azmi – alongside five returning athletes from the Paris 2024 cycle.
• Each athlete will be paired with a Dual Hero Project, a Toyota-supported initiative within the Asia region that gives back to the communities that shaped them.

SINGAPORE, June 5, 2026 /PRNewswire/ — Toyota Motor Asia (TMA) today announced its refreshed line-up of seven Global Team Toyota Athletes (GTTAs) representing six countries across Southeast Asia, on the road to the Aichi-Nagoya 2026 Asian Games and Asian Para Games. The roster includes two new para-athletes, alongside returning athletes from the Paris 2024 cycle. This is also unified under Toyota’s regional brand platform, Move Your World, and reflects the company’s enduring belief that sport reveals what it truly means to be human.

Two new athletes join the Asia line-up

Fresh to the team are Indonesia’s Muhammad Fadli Imamuddin and Malaysia’s Muhammad Ammar Aiman Nor Azmi, who will join five Global Team Toyota Athletes from Indonesia, Malaysia, Philippines, Singapore, Thailand and the Vietnam across a range of sporting disciplines. Since 2018, Toyota has partnered with over 20 Global Team Toyota Athletes in Asia, supporting athletes who not only represent sporting excellence, but also embody the power of movement to drive progress beyond competition. As Toyota continues to evolve, its athlete partnerships remain a key expression of its Move Your World philosophy, where mobility extends beyond movement to create access, opportunity and progress within communities. Through the Global Team Toyota Athletes, Toyota continues to champion sport as a platform for inspiration, inclusion and meaningful community impact.

The full line-up of Global Team Toyota Athletes include:

“At Toyota, sport is a reflection of the human experience — the hope, the doubt, the dignity in defeat and the joy of moving forward together.

Across Asia, our seven Global Team Toyota Athletes embody that spirit, and it is our privilege to stand beside these athletes that continue to inspire and demonstrate how far dedication and courage can take them, both in competition and beyond.

Their journeys highlight the power of sport and its ability to open up new possibilities. Through Move Your World, we aim to support their ambitions in the lead-up to Aichi-Nagoya 2026, and to work alongside them in creating lasting impact in the communities that shaped them.” — Preston Tan, Vice President, Toyota Motor Asia

Dual Hero Projects: Turning Athlete Journeys into Community Impact

As part of the long-standing partnership with athletes in Asia, Toyota continues to drive positive impact through its Dual Hero Projects. Launched in 2018, the initiative pairs each athlete with a Toyota-supported project tied to a cause they care deeply about – extending their impact beyond competition and into the communities that shaped them. Since its inception, the programme has supported over 20 athlete-led initiatives across the region. 

In Singapore, Paralympic swimmer Toh Wei Soong co-created a 16-piece adaptive fashion collection that challenges perceptions of disability through inclusive design. In the Philippines, Paralympic champion Ernie Gawilan led a nationwide coastal cleanup and mangrove restoration initiative, mobilizing more than 1,300 volunteers across 33 sites and planting over 10,000 mangroves – restoring the very waters that accompanied his journey as an athlete. 

Similar Dual Hero Projects will be developed with each Asia GTTA across the span of our partnership with them.

Sport at the heart of Move Your World

As preparations for Aichi-Nagoya 2026 begin, Toyota’s expanded Asia athlete line-up brings together athletes who are not only striving for sporting excellence but also working to move their communities forward. Through sport, advocacy and local action, their journeys reflect the spirit of Move Your World – a belief that movement is most powerful when it opens doors for others.

About Toyota Motor Asia
Toyota Motor Asia is the regional corporate headquarters and subsidiary of Toyota Motor Corporation, based in both Singapore and Thailand.

Toyota Motor Asia leads and supports the Asia Pacific region in Sales and Marketing activities, Service Parts, Accessories and Customer Services, Product Planning, Production Control & Logistic, and Aftersales thus contributing to the overall development of auto industry and the growing economies in the region.

Toyota envisions the future mobility society to bring freedom of movement to all. Moving forward, Toyota will provide a diverse range of mobility services and transportation solutions to people around the world as we transform Toyota into a mobility company.

About Move Your World
Move Your World is Toyota’s regional brand platform across Asia, built on the belief that mobility is more than movement — it is what allows people to participate, to belong and to thrive. Through music, sport and community, Move Your World invites everyone in Asia to look up, to join, and to move the world forward, together.

Source

NANJING, China, June 5, 2026 /PRNewswire/ — NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have been discovered, giving rise to 358 unique fusion-tumor pairings. Patients harboring such fusions generally have a poor prognosis. For advanced solid tumor patients who do not receive targeted therapy, the median overall survival ranges from 10.2 to 12.7 months, and these patients are also at a higher risk of brain metastasis. Meanwhile, the loss of the extracellular domain in NTRK fusions renders antibody-based therapies ineffective. Currently, treatment primarily relies on small-molecule TRK inhibitors that target the kinase domain.^1-3

In terms of tumor type distribution, NTRK fusions are characterized by rare mutations with broad tumor spectrum distribution. On one hand, the incidence of NTRK fusions reaches up to 90% in rare malignancies such as secretory breast carcinoma and infantile fibrosarcoma, and ranges from 5% to 25% in papillary thyroid carcinoma and Spitzoid melanoma. On the other hand, real-world data from approximately 295,000 solid tumor patients worldwide indicate that NTRK fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, NTRK fusion-positive patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma and colorectal cancer make up nearly 50% of all affected cases, representing the key population requiring close clinical attention. In addition, the prevalence of NTRK fusions is higher in East Asian populations, with an overall incidence of approximately 0.4% among Chinese patients. It is estimated that more than 15,000 new cases of NTRK fusion-positive solid tumors are diagnosed in China each year.^4-5

Breaking News: Domestic Next-Generation Tumor-Agnostic Targeted Drug Eratrectinib Approved

On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib, has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.

Efficacy Breakthrough: Eratrectinib Delivers Comprehensive Clinical Benefits

Eratrectinib is a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co.,Ltd.. In pivotal registration clinical trials for patients with NTRK fusion-positive solid tumors, this pan-tumor anticancer agent has demonstrated outstanding efficacy and safety.

Registration study results showed an ORR of 68.5% and a DCR of 85.2%. Among patients followed up for more than 6 months, the ORR reached 89.7% and the DCR was 100%, with a mOS of 40.7 months.⁶

In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission for patients.

Furthermore, for patients with baseline brain metastases, the ORR was as high as 87.5%. For patients previously treated with TRK-TKIs, the ORR reached 47.4%, reflecting robust therapeutic efficacy across these patient groups.

New Hope for Patients with NTRK Fusion Resistance

As a next-generation TRK inhibitor independently developed in China, Eratrectinib delivers durable and deep tumor remission, with potent brain penetration and a favorable overall safety profile. Different from the linear structure of first-generation TRK inhibitors, Eratrectinib features a cyclic molecular structure. Structural optimization reduces off-target risks and effectively prevents the emergence of drug-resistant mutations, endowing the agent with the anti-resistance mechanisms characteristic of second-generation TRK inhibitors.

About Vcare PharmaTech

Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) was co-founded in 2010 by professors from China Pharmaceutical University and overseas returnee experts. As a commercial-stage innovative biopharmaceutical enterprise empowered by AI for differentiated de novo drug design, the Company is dedicated to the development of novel medicines and cutting-edge therapeutics, and has been accredited as a National Key Specialized, Refined, Differential and Innovative “Little Giant” Enterprise.

Headquartered in the Biotech and Pharmaceutical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech owns an intelligent R&D headquarters spanning 21,000 square meters. It has built a full-chain innovation system covering independent new drug R&D and industrialization, ranging from AI-powered differentiated target initiation at the early discovery stage, preclinical candidate identification, integrated collaborative pharmaceutical development to green manufacturing. Boasting a robust talent pipeline, the Company employs over 900 staff members, among whom technical professionals account for more than 84%, including over 200 master’s and doctoral degree holders. Such a highly educated, specialized and innovation-driven core R&D workforce underpins the Company’s sustained technological breakthroughs and product upgrading.

Having engaged in pharmaceutical innovation for 16 years, Vcare PharmaTech adheres to the core strategy of indigenous R&D and innovation, targeting unmet clinical needs via differentiated therapeutic approaches. Centered on addressing treatment resistance, overcoming drug resistance and improving target selectivity, the Company has established a high-quality, diversified and tiered innovative drug pipeline covering major chronic illnesses including cardiovascular and cerebrovascular diseases, inflammatory autoimmune disorders and oncology, with its novel pharmaceutical discoveries positioned for global commercialization.

The Company’s core pipeline candidates feature prominent competitive edges and promising commercial prospects. Eratrectinib (VC004), a next-generation TRK inhibitor and small-molecule targeted anti-tumor agent indicated for solid tumors driven by NTRK gene fusions, delivers tumor-agnostic therapeutic benefits across a broad spectrum of indications and has obtained marketing approval in China. Sumecigrel Capsule, a novel oral P2Y12 receptor antagonist selected four times for China’s National Major Science and Technology Projects, precisely inhibits platelet activation and aggregation to block thrombosis for the prevention and treatment of cardiovascular, cerebrovascular and arterial circulatory disorders; its pivotal confirmatory clinical trials are well underway domestically. VC005, a new-generation highly selective JAK1 inhibitor, is being developed via both oral and topical formulations for full-population treatment of atopic dermatitis with all indications in Phase III clinical trials. The asset is also under clinical development for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases, with robust efficacy and safety data accelerating its clinical progression.

Backed by years of technological accumulation, the Company strives to integrate AI capabilities across the entire value chain from early R&D to manufacturing, establishing an AI-enabled premium innovative drug development system and specialized technical platforms. Its R&D platforms have been officially accredited as Nanjing Key Laboratory for AI-Assisted Drug Design and Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry; its AI-directed site-specific enzyme mutation technology has been recognized as Advanced Cleaner Production Technology by Nanjing authorities. Over the past five years, the Company has secured aggregate financing exceeding RMB 1.2 billion, earning strong recognition from the capital market.

Moving forward, abiding by its founding mission of “The better Care, The better Medicines”, Vcare PharmaTech will keep advancing AI-driven original innovation and cutting-edge pharmaceutical technologies while expanding its footprint across domestic and overseas markets. Leveraging robust R&D strengths to build a differentiated novel drug portfolio, the company commits to delivering superior therapeutic options for patients worldwide and evolving into a globally influential innovative pharmaceutical enterprise.

References:

1. Nguyen MA, et al. Pathology. 2023 Aug;55(5):596-609.
2. Jiang T, et al. Acta Pharm Sin B. 2021 Feb;11(2):355-372.
3. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747.
4. O’Haire S, et al. Sci Rep. 2023 Mar 13;13(1):4116.
5. Qi C, et al. Int J Cancer. 2023 Dec 1;153(11):1916-1927.
6. Vcare Pharma. Phase II Clinical Study Data of Eratrectinib[R]

Commercial Cooperation:
Strategic Development Director: Dr. Peng, peng_yuran@vcarepharmatech.com
BD Director: Liam, xu_minghua@vcarepharmatech.com

Source

HONG KONG, June 5, 2026 /PRNewswire/ — In Q1 2026, Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC). This milestone reinforces its position as a premium, innovation-driven leader in the smart home industry.

Dreame Robot Vacuum has expanded to over 120 countries and regions, opened more than 6,500 flagship stores worldwide, and surpassed 11 million cumulative unit shipments. It holds the No.1 market share in 30 countries—including over 50% in 10—supported by a sustained annual growth rate exceeding 100% for six consecutive years.

The product portfolio features industry-leading, world-first technologies, enabling devices to clean lower, reach deeper, climb higher, and operate more intelligently in real home environments. Each innovation addresses real household cleaning challenges, translating advanced technology into practical everyday value.

“Achieving No.1 globally in both sales and revenue in Q1 2026, according to IDC, marks a significant milestone for Dreame Robot Vacuum,” said Michael MENG, President of Dreame Robot Vacuum. “It reflects our long-term commitment to innovation, quality, and user-centric design. We will continue pushing the boundaries of home robotics to create smarter and more meaningful living experiences for users around the world.”

Looking ahead, Dreame Robot Vacuum will continue expanding its presence in the smart home industry, moving beyond floor cleaning toward the next generation of intelligent robotic automation.

About Dreame Technology
Established in 2017, Dreame Technology is an innovative consumer product company that focuses on smart home cleaning appliances with the vision to empower lives through technology. For more information, visit https://global.dreametech.com.

Source

VANCOUVER, BC, June 5, 2026 /PRNewswire/ — Pinnacle Food Group Limited (Nasdaq: PFAI) (the “Company”), today announced the dismissal of Wencai Pan as Chief Financial Officer and appointment of Dr. Yunhao Chen as Chief Financial Officer of the Company, both effective June 1, 2026.

Dr. Chen has extensive public company finance, accounting, U.S. GAAP, SEC reporting and compliance experience. She served as Chief Financial Officer of Massimo Group from its initial public offering in May 2023 through January 2026 and as a director from April 2024 through January 2026, where she led that company through its initial public offering process in 2024, and directed and managed the company’s financial reporting, investor relations, and capital market functions. From May 2017 to July 2023, Dr. Chen served as Chief Financial Officer of Dogness International Corporation, where she led the company through its initial public offering process in 2017 and directed and managed the company’s financial reporting, investor relations, and capital market functions, and served as the Chief Executive Officer of its U.S. subsidiary from 2018 to 2023. Dr. Chen has extensive knowledge and experience with U.S. GAAP and SEC reporting and compliance requirements. As part of her professional experience, she served as an invited speaker at an SEC forum advocating for small public companies in 2025, successfully executed multiple public offerings for publicly traded companies, conducted analyses and research regarding a large amount of formal filings of SEC registrants, and served on the boards of several public companies. Dr. Chen holds a Ph.D. in Accounting and an MBA in Finance and MIS from the University of Minnesota, and a Bachelor of Economics degree from the University of International Business and Economics. From 2007 to 2014, she served as a faculty member at the University of Miami and Florida International University.

“We are pleased to appoint Dr. Chen as Chief Financial Officer,” said Jiulong You, Chief Executive Officer of Pinnacle Food Group Limited. “Her experience as a public company CFO, together with her background in U.S. GAAP, SEC reporting, internal controls and capital markets, makes her well suited to lead our finance function as we continue to grow as a Nasdaq-listed company.”

Dr. Chen has served as an independent director of the Company since April 2025. In connection with her appointment as Chief Financial Officer, Dr. Chen will cease to serve as an independent director.

About Pinnacle Food Group Limited

Pinnacle Food Group Limited (Nasdaq: PFAI) is a technology-driven company operating at the intersection of smart agriculture and bio-engineering. The Company’s “Dual-Engine” strategy integrates Farming-as-a-Service solutions with precision fermentation and synthetic biology platforms to support the development of efficient and sustainable food systems. For more information, please visit the Company’s website at www.pinnaclefoodinc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws. These statements include, but are not limited to, statements regarding the Company’s management transition, finance function, public company reporting and compliance functions, internal controls, business strategy, and future operations.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks relating to the Company’s ability to successfully transition its finance and accounting functions, maintain effective disclosure controls and internal control over financial reporting, comply with U.S. GAAP, SEC reporting and Nasdaq requirements, execute its “Dual-Engine” strategy, and manage its smart agriculture, precision fermentation and synthetic biology initiatives, as well as other risks described in the Company’s filings with the Securities and Exchange Commission.

The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Source

SYDNEY, June 5, 2026 /PRNewswire/ — Trip.com, the global travel service provider, has officially launched its End of Financial Year (EOFY) Mega Sale, kicking off the winter travel season in style. From the week commencing 9 June 2026, Aussie travellers can access weekly rolling discounts, flash sales, and coupon drops designed to turn dream holidays into an affordable reality.

The EOFY Mega Sale is a chance to save big across flights, hotels, and travel essentials—with four big weekly drops starting from 9 June.

EOFY Mega Sale Calendar:

• Week 1 (9 June) — Travel Essentials Launch: Up to 50% off coupons for attractions and eSIMs, a free eSIM coupon (valued up to $2), 30% off car hire coupon, plus Buy 1 Get 1 Free offers on selected attractions
• Week 2 (16 June) — Hotel Mega Deals: Up to 70% off hotel coupons in addition to flash sales on accommodation from $9 per night
• Week 3 (23 June) — Flight Frenzy:
  • $29 domestic flights between Sydney, Melbourne, Brisbane, Gold Coast and Adelaide
  • $109 flights from Perth to Bali
  • $149 flights from Sydney, Melbourne, and Brisbane to Bali and Ho Chi Minh City
  • Up to 50% off flight coupons
• Week 4 (30 June) — Last Chance Deals: Final opportunity to secure the month’s best travel bargains before the financial year closes.

Even Bigger Savings – Partner Airlines & Airports

Alongside the EOFY Mega Sale, Trip.com has teamed up with leading airlines and airports to deliver significant direct savings for Australians travelling overseas.

• This Is China: From today to 27 July, snag up to $100 off on flights from Sydney to China, valid across premium carriers including China Southern, China Eastern, Air China, and more. Flash sales are also available for flights from Sydney to Shanghai at $189 on 9 June and 7 July, and the same price also applies for flights from Sydney to Beijing on 23 June and 21 July.
• Brisbane Airport – Take Off To Asia: Queenslanders can score $50 off flights heading into Asia’s popular hubs from today until 14 June.
• Fly with Batik Air: Discover Southeast Asia with up to $100 off flights from Sydney to destinations across Indonesia and Malaysia.
• Premium Global Airline Savings:Enjoy an instant $100 off for bookings with Malaysia Airlines with more airline partner discounts to be announced in due course.

Don’t Miss Out – Get Ready Now

Download the Trip.com app now to grab these limited-time offers.

Terms and Conditions apply. All promotional offers are available on a first-come, first-served basis within the specified period and while stocks last. Please note that all deals are in AEST time.

For more information, please visit https://au.trip.com/.

About Trip.com

Trip.com is an international one-stop travel service provider, available in 27 languages across 48 countries and regions in 44 local currencies. Offering an extensive hotel and flight network of more than 1.7 million hotels and flights from over 680 airlines, along with over 350,000 in-destination activities, Trip.com covers 3,500 airports in 220 countries and regions. Trip.com‘s world-class 24/7 multilingual customer service helps to ‘create the best travel experience’ for its millions of customers worldwide. To book your next trip, visit Trip.com.

Source

The partnership unites two organizations with New Zealand roots and growing global profiles at a moment when both are expanding their presence on the international stage

SAN FRANCISCO and AUCKLAND, New Zealand, June 5, 2026 /PRNewswire/ — Ivo, the leading platform for AI contract intelligence, today announced a partnership with New Zealand Football to become the Official Legal AI Partner of the All Whites, New Zealand’s men’s national team.

The collaboration reflects Ivo’s continued connection to its New Zealand origins as the company expands its global footprint. Founded in Auckland and now headquartered in San Francisco, Ivo helps global enterprises, including Meta, Uber, IBM, Shopify, and Mitsubishi Electric, accelerate contract workflows and surface critical business intelligence locked inside their contract portfolios.

As part of the partnership, Ivo branding will appear on the front of the All Whites’ training and press kit as the team prepares to compete on the sport’s biggest international stage, as well as across select New Zealand Football initiatives. New Zealand Football will exclusively use Ivo’s contract intelligence platform to draft, review, and analyze all their teams’ agreements.

The announcement arrives alongside a wave of global momentum for Ivo, which has grown ARR sixfold in the last 12 months and has recently opened offices in London and New York.

“As a New Zealand-founded company, we know what it takes to build something and take it to the world stage,” said Min-Kyu Jung, CEO and co-founder of Ivo. “Standing with the All Whites as they prepare for one of the most significant moments in the program’s history is something we’re really proud of.”

Andrew Pragnell, Chief Executive of New Zealand Football, said: “Ivo is a real Kiwi success story of a company taking on the world, and that’s exactly what we strive to do every time our national teams step onto the field. It’s exciting to partner with a New Zealand-founded company experiencing strong global growth while remaining connected to its roots. We look forward to working together and supporting each other’s continued success.”

About Ivo
Ivo is an enterprise-grade AI-powered contract intelligence platform that enables legal and business teams to move faster, reduce risk, and unlock revenue by turning contracts into actionable business intelligence. Founded in New Zealand and headquartered in San Francisco, Ivo helps organizations surface risk instantly, accelerate negotiation cycles, and remove bottlenecks across the contract lifecycle. Customers include leading global enterprises and high-growth companies across multiple industries.

About New Zealand Football
New Zealand Football oversees the beautiful game in Aotearoa New Zealand. From a player’s first experience of football at a young age through the development pathway to national competitions, refereeing, coaching, administration, and ultimately representing New Zealand on the international stage, New Zealand Football supports every level of the game.

Football is the largest team participation sport in the country, with more than 180,000 registered players in 2025.

New Zealand Football manages national men’s and women’s football, futsal, and eFootball leagues and cup competitions.

As the highest-ranked member association in the Oceania Football Confederation, New Zealand Football runs 10 national team programmes, including the men’s national team, the All Whites, and the women’s national team, the Ford Football Ferns.

Members of the All Whites wearing training kit featuring Ivo branding following the announcement of a new partnership between Ivo and New Zealand Football.

Logo – https://mma.prnasia.com/media2/2995230/Ivo_Logo_Full_Ivy_2x_Logo.jpg?p=medium600
Photo – https://mma.prnasia.com/media2/2995231/Tim_Payne_NZF_3a.jpg?p=medium600

Source: Ivo AI, Inc.

Source

Source: Vespexx Inc.

Source